Cancer risk assessment and the genetic counseling process: Using hereditary breast and ovarian cancer as an example

Medical Principles and Practice

Volumn 17, Issue 3, 2008, Pages 173-189

  Prucka, Sandra K ^a   McIlvried, Dawn E ^a   Korf, Bruce R ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE   (United States)

Author keywords

Genetic counseling; Hereditary breast and ovarian cancer syndrome; Hereditary cancer; Qualitative and quantitative risk assessment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53;

BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; COWDEN SYNDROME; FAMILIAL CANCER; GENE FUNCTION; GENE MUTATION; GENETIC COUNSELING; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HUMAN; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL INFORMATION; OVARY CANCER; PATIENT COUNSELING; PEUTZ JEGHERS SYNDROME; PHENOTYPE; REVIEW; RISK ASSESSMENT;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; OVARIAN NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 42149141754     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000117790     Document Type: Review

References (91)

1. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet 1993;9:138-141.
2. Claus ER, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-242.
3. Willett W: Recent findings regarding lifestyle risk factors in the epidemiology of breast and colon cancer; in Fortner RJ (ed): Accomplishments in Cancer Research. Philadelphia, Lippincott, 1993, pp 164-178.
4. Chen PL, Sellers TA, Rich SS, Potter JD, Folsom AR: Examination of the effect of nongenetic risk factors on the familial risk of breast cancer among relatives of postmenopausal breast cancer patients. Cancer Epidemiol Biomarkers Prev 1994;3:549-555.
5. Kinsler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
6. Hampel H, Sweet K, Westman JA, Offit K, Eng C: Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 2004;41:81-91.
7. Burke W, Culver JO, Bowen D, Lowry D, Durfy S, McTiernan A, Anderson MR: Genetic counseling for women with an intermediate family history of breast cancer. Am J Med Genet 2000;90:361-368.
8. Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, Palomares MR, Lowstuter KJ, MacDonald DJ: Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007;297:2587-2595.
9. Trepanier A, Ahrens M, McKinnon W, Peters J, Stopfer J, Grumet SC, Manley S, Culver JO, Acton R, Larsen-Haidle J, Correia LA, Bennett R, Pettersen B, Ferlita TD, Costalas JW, Hunt K, Donlon S, Skrzynia C, Farrell C, Callif-Daley F, Vockley CW: Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Counsel 2004;13:83-114.
10. Berliner JL, Fay AM: Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the national society of genetic counselors. J Genet Counsel 2007;16:241-260.
11. Lynch HT, Drouhard T, Vasen HF, Cavalieri J, Lynch J, Nord S, Smyrk T, Lanspa S, Murphy P, Whelan KL, Peters J, de la Chapelle A: Genetic counseling in a Navajo hereditary nonpolyposis colorectal cancer kindred. Cancer 1996;77:30-35.
12. Mitchell JL: Cross-cultural issues in the disclosure of cancer. Cancer Pract 1998;6:153-160.
13. American Medical Association: Identifying and managing hereditary risk for breast and ovarian cancer, April 2001.
14. Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer. Cancer 1994;73:643-651.
15. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M; The Breast Cancer Linkage Consortium: genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-689.
16. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cocharn C, Bennett LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 . Science 1994;266:66-71.
17. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-1689.
18. Narod SA, Feunteum J, Lynch HT, Watson P, Conway T, Lynch J, Lenoir GM: Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991;338:82-83.
19. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gergory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-791.
20. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D: Localization of a breast-cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-2090.
21. Szabo CI, King MC: Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013-1020.
22. Struewing JP, Beliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
23. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K: Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126-128.
24. Levey-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:1059-1067.
25. Couch FJ, Weber BL: Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast cancer information core. Hum Mutat 1996;8:8-18.
26. Roe BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187.
27. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259-1272.
28. Rubinstein WS: Hereditary breast cancer in Jews. Fam Cancer 2004;3:249-257.
29. Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K: Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 2004;3:259-264.
30. Myriad Genetics Inc. 2007. www.myriad.com.
31. King MC, Markes JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;303:643-646.
32. Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-419.
33. Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22:735-742.
34. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-1316.
35. Easton DF, Bishop DT, Ford D, Crockford GP, the Breast Cancer Linkage Consortium: Genetic linkage analysis in familial breast and ovarian cancer. Am J Hum Genet 1993;52:678-701.
36. Lakhani SR, Van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 . J Clin Oncol 2002;20:2310-2318.
37. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, Ponder B, Bishop DT, Easton DF: Pathology of ovarian cancer in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:2473-2481.
38. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-2335.
39. Gayther SA, Magion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-105.
40. UT Southwestern Medical Center at Dallas and the Bayes-Mendel Group at Johns Hopkins CancerGene with BRCAPRO, MMRpro, and PancPRO. 2007. http://www4.utsouthwestern.edu/breasthealth/cagene/.
41. Peters JA, Stopfer JE: Role of the genetic counselor in familial cancer. Oncology 1996;10:159-166.
42. Stopfer JE: Genetic counseling and clinical cancer genetics services. Semin Surg Onc 2000;18:347-357.
43. Love RR, Evans AM, Josten DM: The accuracy of patient reports of a family history of cancer. J Chronic Dis 1985;38:289-293.
44. Theis B, Boyd N, Lockwood G, Tritchler D: Accuracy of family cancer history in breast cancer patients. Eur J Cancer Prev 1994;3:321-327.
45. Douglas FS, O'Dair LC, Robinson M, Evans DG, Lynch SA: The accuracy of diagnoses as reported in families with cancer: a retrospective study. J Med Genet 1999;36:309-312.
46. Ziogas A, Anton-Culver H: Validation of family history data in cancer family registries. Am J Prev Med 2003;24:190-198.
47. Hall MA: Genetic discrimination: Fact sheet commissioned by the North Carolina Genomics and Bioinformatics Consortium, LLC, and adapted from materials written for the HEIRS study in conjunction with Jean McEwen at NIH. 2001. www.ncbiotech.org/.
48. Greely HT: Banning genetic discrimination. NEJM 2005;353:865-867.
49. Hall MA, Rich SS: Laws restricting health insurers' use of genetic information: impact on genetic discrimination. Am J Hum Genet 2000;66:293-307.
50. EEOC: Compliance Manual. 1995, vol 2, sect 902, order 915.002, pp 902-945.
51. Lerman C, Lustbader E, Rimer, B, Daly M, Miller S, Sands C: Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Can Inst 1995;87:286-292.
52. Audrain J, Schwartz MD, Lerman C, Hughes C, Peshkin BN, Biesecker B: Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: the contributions of personality and appraisal. Ann Behav Med 1998;19:370-377.
53. American Society of Clinical Oncology: Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-1740.
54. American College of Medical Genetics Foundation: Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines. New York, American College of Medical Genetics Foundation, 1999.
55. MacDonald D, Lessick M: Hereditary cancers in children and ethical and psychosocial implications. J Pediatr Nurs 2000;15:217-225.
56. Biesecker BB: Psychological issues in cancer genetics. Semin Oncol Nurs 1997;13:129-134.
57. Croyle RT: Psychosocial aspects of cancer genetic testing: a research clinicians update. Cancer 1997;80:569-575.
58. Hopwood P: Psychological issues in cancer genetics: current research and future priorities. Patient Educ Counsel 1997;32:19-31.
59. Weil J: Psychosocial Genetic Counseling. New York, Oxford University Press, 2000.
60. Schneider K:Counseling about Cancer: Strategies for Genetic Counselors, ed 2. New York, Wiley-Liss, 2002.
61. Patenaude AF: Genetic Testing for Cancer: Psychological Approaches for Helping Patients and Families. Washington, American Psychological Association, 2005.
62. Facing Our Risk of Cancer Empowered (FORCE). Last updated July 2007. www.facingourrisk.net.
63. Narod SA, Offit K: Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23:1656-1663.
64. Calderon-Margalit R, Paltiel O: Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 2004;112:357-364.
65. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Verr L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 2004;22:1055-1062.
66. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory Group: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
67. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2002;296:185-192.
68. United States Department of Health and Human Services. Last revised August 2007.www.hhs.gov/ocr/hipaa.
69. Menon U, Harper J, Sharma A, Fraser L, Burnell M, Elmasry K, Rodeck C, Jacobs I: Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 2007;22:1573-1577.
70. Spits C, De Ryche M, Van Ranst N, Verpoest W, Lissens W, Van Steirteghem A, Liebaers I, Sermon K: Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenat Diagn 2007;27:447-456.
71. Offit K, Sagi M, Hurley K: Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. JAMA 2006;296:2727-2730.
72. American Society of Clinical Oncology: American Society of Clinical Oncology policy statement update. J Clin Oncol 2003;21:2397-2406.
73. Smith KR, Ellington L, Chan AY, Croyle RT, Botkin JR: Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev 2004;13:733-740.
74. Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, Iddenden R, Woodward ER, Lalloo F, Maher ER, Evans DG: Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet 2007;44:10-15.
75. Goldgar D, Venne V, Conner T, Buys S: BRCA phenocopies or ascertainment bias? J Med Genet 2007;44:e86.
76. Gomez-Garcia EB, Ambergen T, Block MJ, van den Wijngaard A: Patients with an unclassified variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation. J Clin Oncol 2005;23:2185-2190.
77. Calzone KA, Biesecker BB: Genetic testing for cancer predisposition. Cancer Nurs 2002;25:15-25.
78. Claes E, Evers-Kiebooms G, Denayer L, Decruyenaere M, Boogaerts A, Philippe K, Legius E: Predictive genetic testing for hereditary breast and ovarian cancer: psychological distress and illness representations 1 year following disclosure. J Genet Couns 2005;14:349-363.
79. Pasacreta JV: Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: an integrative review. Cancer Invest 2003;21:588-623.
80. Clark S, Bluman LG, Borstelmann N, Regan K, Winer EP, Rimer BK, Skinner CS: Patient motivation, satisfaction, and coping in genetic counseling and testing for BRCA1 and BRCA2. J Genet Couns 2000;9:219-235.
81. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H: BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA 1996;275:1885-1892.
82. DeMarco TA, Peshkin BN, Mars BD, Tercyak KP: Patient satisfaction with cancer genetic counseling: a psychometric analysis of the genetic counseling satisfaction scale. J Genet Couns 2004;13:293-304.
83. Nordin K, Liden A, Hansson M, Rosenquist R, Berglund G: Coping style, psychological distress, risk perception, and satisfaction in subjects attending genetic counseling for hereditary cancer. J Med Genet 2002;39:689-694.
84. Ludwick-Rosenthal R, Neufeld R: Preparation for undergoing an invasive medical procedure: interacting effects of information and coping style. J Consult Clin Psychol 1993;61:156-164.
85. Steptoe A, Sutcliffe I, Allen B, Combes C: Satisfaction with communication, medical knowledge, and coping style in patients with metastatic cancer. Soc Sci Med 1991;32:627-632.
86. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002;71:432-438.
87. The CHEK2 Breast Cancer Case-Control Consortium: CHEK2 *1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74:1175-1182.
88. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, SEARCH collaborators: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-1093.
89. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-874.
90. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA. SEARCH investigators: Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 2007;3:e42.
91. Bennet RL, Steinhaus KA, Uhrich SB, O'Sullivan CK, Resta RG, Lockner-Doyle D, Markel DS, Vincent V, Hamanishi J: Recommendations for standardized human pedigree nomenclature. Am J Hum Genet 1995;56:745-752.